Vertex Pharmaceuticals Logo

Email this page: News Release

Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia

For security reasons, registration is required before you can use this feature.
* Indicates required field